Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(9)
•••
Post by Longies123on Feb 14, 2020 3:29pm
293 Views
Post# 30693329

All be careful

All be careful I once had a load of shares of a company, I am sure you all know very well named Prometic Life Science symbol PLI. Which at the time many portfolio managers and fund managers on BNN one being Robert said it was a great buy, with a great bioscience technology with close to APPROVAL for their main Drug. And it kept stalling and stalling and the company kept on saying that the FDA was just asking for a couple of small corrections on the packaging and ETC.....Well guess what it never happened...... the company almost failed and then the major stock holder being Thomvest Asset Management Inc  basiclly stole all our shares for  0.015 per share when they were trading at .50 cents per share because the company was tied up for cash. Meanwhile in the quatrely meetings the board of directors were always sayings things are on track and any day now we will have a partmership agreement. ( sound familar )
I have heard this story before I have lost a lot of money on this type of scenario please do not fall victimes to these corrupted CEO's and big Corp's that think for themselves.
I have lost all my money over 300k and I am left with a 1000 shares of Liminal BioScience.
Very dishonest World out there especially in Pharma and it's corporate corruption




 
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities